Related Experiment Video

Updated: Jul 2, 2025

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model
06:02

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

Published on: November 6, 2020

14.7K

Global incidence and mortality of severe fungal disease - Author's reply

David W Denning1

  • 1Manchester Fungal Infection Group, The University of Manchester and Manchester Academic Health Science Centre, Manchester, UK; Global Action For Fungal Infections, Geneva, Switzerland; Infectious Diseases in Global Health, Manchester Fungal Infection Group, Manchester M13 9NT, UK.

The Lancet. Infectious Diseases
|February 23, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

10.6K
An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

5.4K

Related Experiment Videos

Last Updated: Jul 2, 2025

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model
06:02

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

Published on: November 6, 2020

14.7K
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

10.6K
An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

5.4K

Related Concept Videos

Skin Diseases and Disorders01:23

Skin Diseases and Disorders

3.9K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
3.9K

Articles linked to this work by shared authors, journal, and citation graph.

Economic burden of chronic pulmonary aspergillosis in Uganda: a cost-of-illness analysis.

IJID regions·2026

COPD and Aspergillus-a complex interaction of global health importance.

The Lancet. Infectious diseases·2026

Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.

American journal of respiratory and critical care medicine·2026

Evaluation of three Aspergillus antibody assays for screening of chronic pulmonary aspergillosis: prospective diagnostic accuracy study.

Diagnostic microbiology and infectious disease·2026

The black aspergilli (Aspergillus niger complex) and their role in human, animal, and plant diseases.

Clinical microbiology reviews·2026

Chronic Pulmonary Aspergillosis in Children: A Scoping Global Review.

Open forum infectious diseases·2026

When the fungus is susceptible, but the patient is not: reading antifungal susceptibility from bench to bedside.

The Lancet. Infectious diseases·2026

Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study.

The Lancet. Infectious diseases·2026

Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6-17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial.

The Lancet. Infectious diseases·2026

Methodological quality and risk of bias in non-randomised comparative effectiveness studies of invasive mould infections: a systematic review.

The Lancet. Infectious diseases·2026

Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial.

The Lancet. Infectious diseases·2026

The risk of mpox false positive results in high transmission settings: evidence from a multi-site observational study in DR Congo.

The Lancet. Infectious diseases·2026

Kyasanur Forest Disease: feasible strategies for vaccine development and evaluation.

The Lancet regional health. Southeast Asia·2026

Kyasanur forest disease: A brief overview and relevance to public health in the Czech Republic.

Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne·2026

Wood type influences tree responses to recurring hot and dry summer tree water deficits across European forests.

European journal of forest research·2026

Inhalation therapies in interstitial lung diseases.

Expert opinion on drug delivery·2026

Bacterial endophytes suppress collar rot of chickpea caused by Sclerotium rolfsii through antagonism and defense enzyme induction.

Frontiers in microbiology·2026

Filovirus reactive antibodies in wildlife hunting communities suggest ongoing zoonotic spillover in forested Guinea.

Nature communications·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us